We have shown that SRA acts as an important regulator capable of dampening the immunostimulatory function of DCs in promoting T cell-mediated antitumor immunity (16–21), suggesting that targeted inhibition of this immunosuppressor may lead to improved DC functionality for T cell priming and DC-targeted cancer immunotherapies (22). Here, MSR1 is linked to cancer.